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There is increasing evidence that systemic inflammatory response has a positive correlation with a poorer outcome in patients
undergoing resection for solid tumours. The aim of this study was to analyse the impact of an elevated C-reactive protein (CRP), an
outcome following curative resection for colorectal liver metastases. One hundred and seventy patients who underwent curative
resection for colorectal liver metastases were included in the study. Laboratory measurements of haemoglobin, white cell, platelets,
albumin and CRP were taken on the day before surgery. Elevated CRP (410mgl
 1) was present in 54 (31.8%) patients. The median
survival of patients with an elevated CRP was 19 months (95% CI 7.5–31.2 months) compared to 42.8 months (95% CI 33.2–52.5
months) for those with a normal CRP, P¼0.004. Similarly, when assessing disease-free survival, patients with an elevated CRP had
poorer disease-free survival (median of 11.8 months (95% CI 6.4–17.3) compared to median of 15.1 months (95% CI 11.1–19.1)),
P¼0.043. The result of the study showed that an elevated preoperative CRP is a predictor of poor outcome in patients undergoing
curative resection for colorectal liver metastases.
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Colorectal cancer is the third commonest malignancy in UK
with around 32000 people diagnosed with colorectal cancer each
year (Cancerstats, 2003; www.cancerresearchuk.org). Of that,
around 20–25% of patients will have liver metastases (CRLM) at
presentation and a further 40–50% will develop metachronous
CRLM following colorectal surgery. Over the last two decades, liver
resection has been established as the standard therapy for CRLM
and offers the best chance of a potential cure with a 5-year survival
of over 40% (Finch et al, 2006; Simmonds et al, 2006). However,
disease recurrence is common with about two-thirds of patients
who had liver resection for CRLM developing recurrent disease,
and half of these patients had the disease recur in the remnant liver
(Steele et al, 1991; Nordlinger et al, 1994; Fong et al, 1997; Hamady
et al, 2006).
Several studies have looked for possible prognostic factors
indicating poor survival outcome and disease recurrence after
initial liver resection for CRLM (Fong et al, 1999; Seifert et al, 2000;
Takahashi et al, 2003; Tanaka et al, 2004; Hamady et al, 2006).
Primary colorectal adenocarcinoma stage and grade, size, distri-
bution and number of liver metastases, presence of extrahepatic
disease, resection margins and lymph nodes status are among
the potential prognostic factors but to date, no consensus have
been reached.
Recently, there is increasing evidence that inflammation, both
local and systemic, has a causal link in the pathogenesis of many
solid tumours (Balkwill and Mantovani, 2001; Coussens and Werb,
2002). Infiltration of proinflammatory macrophages, cytokines and
chemokines in the tumour microenvironment predispose the
tumour to further progression, growth, invasion and metastasis.
Gunter et al (2006) showed an association between chronic low-
grade inflammation, as evidenced by elevated C-reactive protein
(CRP), with an increased risk of colorectal cancer. In addition,
raised CRP is associated with an increased risk of developing
early recurrence and poor outcome following colorectal surgery
(McMillan et al, 1995, 2003; Canna et al, 2005). This suggests that it
is not only the intrinsic properties of tumour cells that determine
invasion and metastasis, but also the tumour microenvironment.
The aim of this study is to examine the relationship between
inflammation, as evidenced by elevated CRP measured before
surgery and outcome in patients who had liver resection for
CRLM.
MATERIALS AND METHODS
Patients undergoing resection for colorectal liver metastases
had CRP measured preoperatively. CRP (reference range being
10mgl
 1 or less) measurements were taken on the day before
surgery with none of the patients showing clinical signs of sepsis.
The criteria for acceptance for surgery included fitness for major
resection and lack of disseminated or irresectable extrahepatic
disease identified by computerised tomography (CT) or MRI scan.
In all cases, the colorectal primary had been previously resected
and the patients had recovered fully from that procedure. Patients
who underwent neo-adjuvant therapy were excluded from this
study. Intraoperative ultrasound was used as an adjunct to the
preoperative radiological investigations. Resection was performed
using the Cavi-Pulse Ultrasonic Surgical Aspirator (CUSA, Model
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s200T, Valley Lab., Boulder, CO, USA). If necessary, an intermittent
Pringle manoeuvre was used with 15min of ischaemia followed by
5min of reperfusion.
In accordance with our unit protocol, all patients undergoing
liver resection were offered adjuvant therapy in the form of 5-FU/
folinic acid, unless they had received adjuvant therapy following
their colonic resection within the past one year.
Patients were followed up at specialist clinics, with a minimum
follow-up period of 1 year at the time of writing (range 1 5 years;
median 28 months). No patients were lost to follow-up. An
intensive policy of postoperative surveillance exists within this
unit. Patients have three monthly chest and abdominal CT
performed during the first postoperative year, then 6 monthly
during year 2. From year 3 to 5, a CT scan is performed yearly and
finally at year 7 and year 10 of follow-up. Tumour markers
carcinoembryonic antigen ((CEA), CA19-9) and liver function tests
are performed during each clinic visit. The data examined included
patient demographics; liver resection histology; prehepatectomy
CEA and CA19-9 tumour marker; prehepatectomy CRP; post-
operative morbidity/mortality results as well as recurrence and
survival figures.
STATISTICS
An SPSS version 9 statistical programme was used to analyse
the data. The Student’s t-test and w
2 tests were used to analyse
differences among groups of patients with high or normal CRP.
Where variables did not follow a normal distribution, the Mann–
Whitney test was applied. Kaplan–Meier survival curves were
used to analyse patient outcome. Patients who died in the posto-
perative period were excluded from the analysis of outcome. A Cox
regression analysis was then performed in a step-wise manner in
order to perform a multivariable analysis of clinico-pathological
factors that impact both overall and disease-free survival.
RESULTS
A total of 170 patients were included in this study. Of these
patients, 106 (62%) were males and 64 (38%) females. The mean
age of patient at time of surgery was 64 years (range 37–87 years;
s.d. 9.86 years). A total of 86 (50.6%) patients had synchronous
disease. All patients underwent liver resection. There were 76
(44.7%) patients who underwent an anatomical resection, a further
45 (26.5%) patients underwent a combination of anatomical
and nonanatomical resection whereas the remaining 49 (28.8%)
patients underwent a nonanatomical resection. A total of 57% of
patients had a ‘major’ (three or more Couinaud segments)
resection performed. The in-hospital mortality rate was 3% and
29 (17%) patients had postoperative complications.
Preoperative CRP was elevated (410mgl
 1) in 54 (31.8%)
patients. The differences in the clinico-pathological features of
patients with a normal compared to an elevated CRP are presented
in Table 1. Of note is that patients with an elevated CRP had no
significant differences in the ‘T’ or ‘N’ stage of the primary tumour.
However, patients with an elevated CRP tended to have larger
metastases as well as increased CA19-9 levels compared to those
with normal CRP.
Outcome
Overall there were 80 (47%) patients who died during the time
period of this study. Of these, there were six non-cancer-related
deaths. Thus, the cancer-specific survival was 56%. The median
survival of patients with an elevated CRP was 19 months (95% CI
7.5–31.2 months) compared to 42.8 months (95% CI 33.2–52.5
months) for those with a normal CRP, P¼0.004 (Figure 1).
Similarly, when assessing disease-free survival, patients with an
elevated CRP had poorer disease-free survival (median of 11.8
months (95% CI 6.4–17.3) compared to median of 15.1 months
(95% CI 11.1–19.1)), P¼0.043 (Figure 2). The results of univariate
and multivariable analysis of the predictors of overall survival are
shown in Tables 2 and 3, respectively. Of note is the fact that an
elevated CRP was the only predictor of poor survival on univariate
analysis. However on multivariable analysis, an elevated CRP as
well as primary ‘T’ stage both predicted for poorer overall survival.
When the multivariable analysis was repeated for disease-free
Table 1 Clinico-pathological features
Factor
Normal CRP
(10mgl
 1 or
less) (N¼116)
Elevated CRP
(410mgl
 1)
(N¼54) Significance
Age (mean) 63.7 64.7 0.577
Synchronous disease 56 30 0.502
Male gender 73 33 0.802
Multiple (4 or more)
metastases
27 12 0.568
Primary nodal status
N0 32 10 0.371
N1 51 27
N2 9 6
Primary T stage
T1 1 3 0.111
T2 8 3
T3 57 19
T4 24 15
CEA 61.5 63 0.820
CA19-9 53.9 70.9 0.013
Large metastases size
(4 50mm)
34 31 0.003
Positive margin 23 15 0.641
CEA¼carcinoembryonic antigen; CRP¼C-reactive protein. Mann–Whitney U-test.
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Figure 1 Overall survival stratified according to CRP.
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outcome, P¼0.011 (HR 4.07; 95% CI 1.36–12.19).
DISCUSSION
Tumour progression is a complex process that depends not
only on the intrinsic properties of the tumour, but also on its
interaction with the host cells. Although the link between
inflammation and cancer was first proposed by Virchow in 1863,
it is only in last two decades that we are beginning to delineate and
have an understanding of this intricate network of interactions.
This study showed that elevated preoperative CRP present in
almost one-third of patients with CRLM and is associated with a
poor overall as well as disease-free survival in patients who had
liver resection for colorectal metastases. This is consistent with
other studies that found a positive correlation between elevated
CRP concentrations, before surgery and a poor outcome in
patients who had curative primary tumour resection (Nozoe et al,
2001; McMillan et al, 2003; Canna et al, 2005; Crumley et al, 2006).
However, this is the first study to identify such a relationship
among patients who have undergone curative resection for CRLM.
This finding has important implications for selection of patients
for surgery and the presence of an elevated CRP should be
considered when counselling patients upon the likelihood of a
‘curative resection’.
We also found that elevated CRP was associated with presence
of larger metastases size and elevated CA19-9. It is possible that
any impact upon survival of an elevated CRP may be as a result
of this association. However, as neither of these factors were
independent predictors of survival on multivariable analysis, it
appears that the elevated CRP is the main factor contributing
to the poorer outcome among these patients. Interestingly, there
was no association between ‘T’ and ‘N’ characteristics of the
primary and an elevation in CRP.
The basis for the relationship between elevated CRP and poor
prognosis is unclear and there are several possible explanations.
Elevated CRP level may simply reflect a nonspecific inflammatory
response to tumour necrosis or local tissue damage. Alternatively,
it may be indicative of a favourable environment for the
establishment and growth of distant metastases. Serum level of
vascular endothelial growth factor (VEGF), an angiogenic factor,
is increased in the presence of raised CRP concentration
(Xavier et al, 2006). Angiogenesis plays an important role in
tumour growth and is associated with a poor outcome in patients
with GI tumours (Tanigawa et al, 1997; Fondevila et al, 2004).
In addition, interleukin (IL) -1 and -6 network is upregulated
(Vidal-Vanaclocha et al, 2000; Miki et al, 2004). Interleukin 1 is
involved in the development of metastasis in animal studies and
IL-6, apart from being a growth factor, promotes resistance to
apoptosis (Vidal-Vanaclocha et al, 1994, 2000; Chauhan et al, 1997;
Frassanito et al, 2001; Jee et al, 2001). This creates a micro-
environment that favours tumour angiogenesis, proliferation,
growth and metastases.
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Figure 2 Disease-free survival stratified according to CRP.
Table 2 Univariate analysis of overall survival
Factor P-value
Older age (years) 0.536
Gender (males) 0.522
CEA 0.353
CA19-9 0.838
Large (450mm) 0.661
metastases size
Positive resection 0.461
Margin
Synchronous 0.309
disease
Primary tumour 0.754
nodal positivity
Poorer tumour 0.124
primary T-stage
Multiple (4 or more) 0.244
Metastases
Poor clinical risk score 0.972
Elevated CRP o0.001
CEA¼carcinoembryonic antigen; CRP¼C-reactive protein. MSKCC clinical risk
score – poor scores defined as scores 3–5 (Fong et al, 1999).
Table 3 Multivariable analysis of overall survival
Factor
Hazard ratio (95% confidence
interval) P-value
Older age (years) 1.04 1.00–1.09 0.051
Gender (males) 1.09 0.51–2.32 0.816
CEA 0.99 0.99–1.00 0.785
CA19-9 0.99 0.99–1.00 0.766
Large (450mm) 0.99 0.97–1.01 0.827
metastases size
Positive resection 0.56 0.11–2.86 0.488
Margin
Synchronous 0.92 0.43–1.95 0.836
disease
Primary tumour 0.60 0.30–1.19 0.149
nodal positivity
Poorer tumour 1.82 1.10–3.00 0.019
primary T-stage
Multiple (4 or more) 2.06 0.91–4.66 0.785
Metastases
Poor clinical risk 0.707 0.21–2.61 0.747
score
Elevated CRP 2.86 1.09–7.49 0.032
CEA¼carcinoembryonic antigen; CRP¼C-reactive protein. MSKCC clinical risk
score– poor scores defined as scores 3–5 (Fong et al, 1999).
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tumour growth. An impaired host immune response, evidenced
by a weak lymphocyte infiltration at tumour margin, is asso-
ciated with a poor prognosis in patients who had liver resection
for CRLM (Okano et al, 2003). There is an inverse relation-
ship between CRP levels and tumour lymphocyte infiltration,
with a raised CRP concentration indicative of a weak infiltra-
tion of lymphocytes at the periphery of the tumour (Canna
et al, 2005). The significance of systemic inflammatory
response in the pathogenesis of cancer has important clinical
implications.
Several novel therapies targeting the inflammatory pathways are in
clinical trial (Balkwill and Mantovani, 2001). Tumour necrosis factor
(TNF) antagonists, chemokine and IL-6 antagonism, nonsteroidal
anti-inflammatory agents and statin drugs are among the potential
therapies. Selective Cox-2 inhibitors were of particular interest with
promising initial results but adverse cardiovascular risks have limited
their usage (Mukherjee et al, 2001; Thun et al,2 0 0 2 ;Y a uet al, 2003).
In summary, the results of this study showed that elevated CRP
levels, measured before surgery, are present in a significant propor-
tion of patients with CRLM. This is found to predict for a poor
survival outcome in patients who had liver resection performed.
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